Marta Peri1,2, Edoardo Botteri3, Eleonora Pisa4, Filippo De Marinis5, Antonio Ungaro1, Francesca Spada1, Chiara Maria Grana6, Roberto Gasparri7, Lorenzo Spaggiari7, Nicole Romentz3, Giuseppe Badalamenti2, Antonio Russo2, Nicola Fazio1. 1. Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, Milan, Italy. 2. Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, Palermo University Hospital, Palermo, Italy. 3. Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy. 4. Division of Pathology, European Institute of Oncology, Milan, Italy. 5. Division of Thoracic Oncology, European Institute of Oncology, Milan, Italy. 6. Division of Nuclear Medicine, European Institute of Oncology, Milan, Italy. 7. Division of Thoracic Surgery, European Institute of Oncology, Milan, Italy.
Abstract
BACKGROUND: Broncho-pulmonary neuroendocrine tumors (bpNETs) are rare malignancies and there is no consensus on therapeutical management of metastatic disease and follow-up after radical resection. METHODS: Clinical records of patients with a cytological or histological diagnosis of bpNETs and distant metastases (metachronous or synchronous), evaluated at the European Institute of Oncology between 1997 and 2014, were retrospectively analyzed. Data on patient demographics, pathology, imaging exams, surgical and non-surgical treatments were collected. P value descriptive data, uni- and multi-variate survival analysis were generated for all variables. RESULTS: With a median follow-up of 53 [9-215] months, 61 patients with metachronous and 47 with synchronous metastases were analysed. The most common tool of first recurrence detection was computed tomography. Liver (67%), lymph node (25%), bone (22%) and lung (16%) were the most common sites of relapse. Median time to recurrence was 5 years. Median overall survival (OS) was 72 months for the whole population, with no significant difference between patients with synchronous and metachronous metastases. Age, bone metastases, liver metastases and Ki-67 as a continuous variable all significantly correlated with prognosis at the multivariate analysis. CONCLUSIONS: This is one of the largest, single-centre, series of metastatic bpNETs. Among patients with metachronous metastases the pattern of recurrences was heterogeneous as were the follow-up exams used to detect them. The results of our analysis may represent solid bases for designing prospective clinical trials in homogeneous settings of bpNETs.
BACKGROUND: Broncho-pulmonary neuroendocrine tumors (bpNETs) are rare malignancies and there is no consensus on therapeutical management of metastatic disease and follow-up after radical resection. METHODS: Clinical records of patients with a cytological or histological diagnosis of bpNETs and distant metastases (metachronous or synchronous), evaluated at the European Institute of Oncology between 1997 and 2014, were retrospectively analyzed. Data on patient demographics, pathology, imaging exams, surgical and non-surgical treatments were collected. P value descriptive data, uni- and multi-variate survival analysis were generated for all variables. RESULTS: With a median follow-up of 53 [9-215] months, 61 patients with metachronous and 47 with synchronous metastases were analysed. The most common tool of first recurrence detection was computed tomography. Liver (67%), lymph node (25%), bone (22%) and lung (16%) were the most common sites of relapse. Median time to recurrence was 5 years. Median overall survival (OS) was 72 months for the whole population, with no significant difference between patients with synchronous and metachronous metastases. Age, bone metastases, liver metastases and Ki-67 as a continuous variable all significantly correlated with prognosis at the multivariate analysis. CONCLUSIONS: This is one of the largest, single-centre, series of metastatic bpNETs. Among patients with metachronous metastases the pattern of recurrences was heterogeneous as were the follow-up exams used to detect them. The results of our analysis may represent solid bases for designing prospective clinical trials in homogeneous settings of bpNETs.
Authors: Paul C Lee; Nonso C Osakwe; Navnett Narula; Jeffrey L Port; Subroto Paul; Brendon M Stiles; Weston G Andrews; Abu Nasar; Nasser K Altorki Journal: Thorac Cardiovasc Surg Date: 2015-03-10 Impact factor: 1.827
Authors: James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans Journal: J Clin Oncol Date: 2008-06-20 Impact factor: 44.544
Authors: Giuseppe Cardillo; Francesco Sera; Marco Di Martino; Paolo Graziano; Roberto Giunti; Luigi Carbone; Francesco Facciolo; Massimo Martelli Journal: Ann Thorac Surg Date: 2004-05 Impact factor: 4.330
Authors: Manal M Hassan; Alexandria Phan; Donghui Li; Cecile G Dagohoy; Colleen Leary; James C Yao Journal: Int J Cancer Date: 2008-08-15 Impact factor: 7.396
Authors: Curtis R Chong; Lori J Wirth; Mizuki Nishino; Aileen B Chen; Lynette M Sholl; Matthew H Kulke; Ciaran J McNamee; Pasi A Jänne; Bruce E Johnson Journal: Lung Cancer Date: 2014-08-27 Impact factor: 5.705